Dr Steven Powell, Chief Executive Officer, Cambridge Cognition said: “We are pleased to welcome another pharmaceutical partner to the growing number who trust our neuroscience technologies with the collection and analysis of valuable patient data. In 2018 we took the strategic decision, based on customer input, to enable clients to mitigate risks and reduce operational costs by measuring more outcomes on our proven CANTAB Connect platform. This series of recent contract wins further validates the Company’s strategy and demonstrates our ability to translate customer requirements into revenue rapidly.”
Cambridge Cognition Holdings plc (LON: COG), which develops and markets neuroscience technology to assess brain health, announced today it has won a significant new clinical trial contract, which is the largest in a series of recently signed electronic clinical outcomes assessment (eCOA) trials.
The contract is worth over US$750,000 with a new client for the Company, a specialty pharmaceutical developer, over a one-year period. It is the largest of a number of eCOA contracts won since Cambridge Cognition decided to increase the value of its software service by expanding the capabilities of its CANTAB Connect platform. The technology now enables the assessment of multiple outcomes, in addition to cognitive measures, on a single platform.
This latest contract is for a phase IV trial which will use the Company’s robust eCOA technology to evaluate treatment safety and tolerability with objective computerised cognitive assessments and additional clinician-reported outcome measures delivered to patients on touchscreen devices.
Performing multiple outcome assessments on the validated CANTAB Connect platform integrates data collection, reduces administrative burden and saves costs for study sites while improving data quality throughout the trial.
